FDA grants AstraZeneca six months paediatric exclusivity for Symbicort
26th Jan 2017 11:24
(ShareCast News) - The US Food and Drug Administration has granted AstraZeneca six months of paediatric exclusivity for its Symbicort inhalation aerosol for asthma. The decision was based on the evaluation of trials conducted in children with asthma aged six up to 12 years in response to a written r
Read moreSector movers: BT, Smurfit Kappa move higher after hiking prices
20th Jan 2017 15:53
(ShareCast News) - Cyclicals led gains, spearheaded by oil service and general industrial issues, alongside an advance in stock of BT Group after the UK telecoms incumbent let it be known it would be raising prices for its broadband and landline services. AMEC Foster and Petrofac were up as crude oi
Read moreGlaxoSmithKline nabs Astra's Luke Miels to head global pharma
19th Jan 2017 10:20
(ShareCast News) - The president of GlaxoSmithKline's global pharmaceuticals division, Abbas Hussain, is leaving the company later this year, to be replaced by AstraZeneca's Luke Miels. Miels, who is currently executive vice president of Astra's European business, will report to current chief execut
Read moreAstraZeneca 'enhances options' in immuno-oncology trials for NSCLC
17th Jan 2017 08:24
(ShareCast News) - AstraZeneca has rejigged the target of clinical trials for its immuno-oncology treatment for non-small cell lung cancer after "strong efficacy" of its durvalumab drug shown in recent internal and external data as well as "significant opportunities in the competitive landscape". Th
Read moreSunday newspaper round-up: Hard Brexit, Putin, Hammond
15th Jan 2017 16:35
(ShareCast News) - Theresa May will announce that Britain is seeking a clean and hard Brexit in a speech this week that will promise to create a "strong new partnership" with the European Union. The prime minister will finally lay her cards on the table, making clear that the UK is set to pull out o
Read moreWednesday broker round-up
11th Jan 2017 13:32
(ShareCast News) - Burberry: Barclays upgrades to Overweight and lifts target price from 1450p to 1760p. AstraZeneca: UBS maintains Buy, keeps target price of 5,000p. Spectris: Bank of America Merill Lynch upgrades to Buy with a target price of 2600p. Unilever Plc: UBS maintains Buy with a target
Read moreAstraZeneca completes sale of rights to Pfizer
23rd Dec 2016 07:06
(ShareCast News) - AstraZeneca announced on Friday that it has completed the agreement with Pfizer for the sale of the commercialisation and development rights to its late-stage small molecule antibiotics business, comprising the approved antibiotics Merrem, Zinforo and Zavicefta, and ATM-AVI and CX
Read moreTuesday newspaper round-up: Tax havens, Lagarde, AstraZeneca, Brexit
20th Dec 2016 07:20
(ShareCast News) - The UK's overseas territories face renewed pressure to abandon corporate secrecy after 80 MPs joined forces to demand greater financial transparency from offshore havens. The cross-party group is backing an amendment to the government's criminal finances bill on Tuesday that would
Read moreFTSE 100 movers: Pharmaceutical stocks lead FTSE's rally
16th Dec 2016 14:11
(ShareCast News) - The FTSE 100 rose 0.11% to 7,006.73 points on Friday afternoon with pharmaceutical stocks leading the way. Hikma Pharmaceuticals, Shire and Astrazeneca rallied on a positive read-across following reports Sanofi is in advanced talks to acquire Actelion. The companies are said to b
Read moreMonday broker round-up
12th Dec 2016 15:55
(ShareCast News) - Greencore: Berenberg reiterates buy with a target price of 350p. Talk Talk: UBS reiterates neutral, 160p target. Barclays: JP Morgan reiterates neutral with a 215p target. Bunzl: Deutsche Bank reiterates buy with a 2450p target. Old Mutual: Barclays downgrades to equal-weight w
Read moreAstraZeneca co-develops treatment for Alzheimer's disease
9th Dec 2016 12:14
(ShareCast News) - Pharmaceutical giant AstraZeneca has teamed up with American counterpart Eli Lilly to co-develop a treatment for Alzheimer's disease (AD). The treatment, called MEDI1814, an antibody selective for amyloid-beta 42,and is currently in Phase 1 trials as a potential disease-modifyi
Read moreWednesday broker round-up
7th Dec 2016 13:36
(ShareCast News) - BHP Billition: HSBC reiterates hold with a target price of 1200p. Bunzl: Goldman Sachs reiterates neutral, 2200p target. Bellway: JP Morgan reiterates overweight with a 2950p target. Aviva: RBC reiterates outperform with a 500p target. IG: Barclays stays at overweight with a 95
Read moreAstraZeneca's Tagrisso cuts lung cancer progression by 70%
6th Dec 2016 09:48
(ShareCast News) - AstraZeneca said on Tuesday that data from a Phase III trial of Tagrisso has shown the medicine is superior to standard chemotherapy for the treatment of lung cancer. The pharmaceuticals giant said the medicine was shown to reduce the risk of lung cancer progression by 70% compare
Read moreAstraZeneca completes sale of US rights for nasal spray
5th Dec 2016 07:05
(ShareCast News) - AstraZeneca has completed the sale of rights to its nasal spray outside of the US with Swiss pharmaceutical Cilag for $330m. The FTSE 100 company sold the rights for Rhinocort Aqua, a nasal spray to treat allergic and nonallergic rhinitis and polyps, for use outside of the US to a
Read morePharma stocks to outperform versus Miners as US dollar gains, Deutsche Bank says
1st Dec 2016 09:42
(ShareCast News) - Pharmaceuticals' recent underperformance versus Mining stocks might be set to end, strategists at Deutsche Bank said. The approximately 5% gain in the US dollar index over the past three months would have been consistent with double-digit outperformance by the former, the investme
Read more